Navigation Links
New biomarker may help in detecting gliomas, reports Neurosurgery
Date:1/16/2013

Philadelphia, Pa. (January 16, 2013) Researchers using sophisticated genetic testing techniques have identified a promising new biomarker for diagnosis of gliomathe most common type of malignant brain tumor, reports the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

The biomarker ELTD1 "may serve as an additional biomarker for gliomas in preclinical and clinical diagnosis of gliomas," according to the study by Rheal A. Towner of Oklahoma Medical Research Foundation, Oklahoma City.

Biomarker Reflects Rapid Blood Vessel Development

Dr. Towner and colleagues used advanced "data mining and bioinformatic" techniques to evaluate genes and gene products potentially associated with gliomas. Glioma is a general term referring to tumors originating in the glial cells of the brain and spinal cord. Gliomas make up about 40 percent of all brain tumors and 80 percent of central nervous system cancers. Especially for advanced (high-grade) gliomas such as glioblastoma multiforme (GBM), expected survival is very poor.

Out of nearly 200 possible markers analyzed, ELTD1 was identified as the strongest candidate for a significant association with glioma. There's special interest in ELTD1 because it is linked to development of new blood vessels, or angiogenesisa characteristic of rapidly growing cancers. (ELTD1 stands for "epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1.")

Studies in human patients suggested that ELTD1 was strongly associated with gliomas. ELTD1 was more highly expressed in specimens from 50 patients with high-grade gliomas, compared to 21 patients with lower-grade gliomas.

Higher levels of ELDT1 expression were associated with a higher grade of glioma, and with lower survival. ELTD1 compared well with other known markers of glioma, such as vascular endothelial growth factor. It also appeared to be associated with one specific subtype of GBM (mesenchymal GBM).

In further experiments, the researchers transplanted glioma cells into the brains of rats. As the tumors developed, they showed elevated levels of ELTD1, compared to normal brain tissue. The rat studies included evaluation of a "molecular MRI technique" for measuring ELDT1 levels in the living brain.

A Helpful Marker for Glioma Diagnosis?

Even with modern treatments, GBM and other malignant gliomas are devastating cancers. In recent years, advances in research have led to the identification of biomarkers associated with glioma. Dr. Towner and colleagues write, "Validation of more biomarkers for GBM could be beneficial in the diagnosis and therapeutic intervention of this disease."

With further study, ELTD1 could become a useful new marker of glioma, including GBM. Gliomas show increased expression of ELTD1, and higher levels of ELTD1 expression are associated with higher tumor grade and a worse prognosis. "Any increase in ELTD1 will more than likely be associated with increased angiogenesis or neovascularization [new blood vessel development] in gliomas," the researchers write.

Although the findings are only preliminary, Dr. Towner and coauthors suggest that ELTD1 could be useful in detecting the presence and grade of gliomasparticularly high-grade gliomas such as GBM. They conclude, "[T]his biomarker may play an important diagnostic role in addition to currently used markers for gliomas, particularly as a histological marker for identifying vascular proliferation."


'/>"/>
Contact: Connie Hughes
connie.hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
2. Biomarkers can reveal IBS
3. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
4. Early biomarker for pancreatic cancer identified
5. New biomarker test predicts arthritis at much earlier stage, MU researchers say
6. Biomarker predicts response to cancer treatment
7. Novel biomarkers reveal evidence of radiation exposure
8. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
9. Using biomarkers to identify and treat schizophrenia
10. US Army: Pre-injury cartilage biomarkers associated with subsequent ACL injuries
11. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is a ... mind and move the readers one step closer to God. “Psalms of Humidity” is ... his mistakes that have been made within his life are the very same things ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring ... their closets. “They Sang At Her Funeral” is the creation of published author, Annalise ... five children and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to ...
(Date:9/19/2017)... ... 19, 2017 , ... Only a few physicians were selected to receive the ... A. Clevens, MD, FACS . The founder and medical director of Clevens Face ... trained at Yale, Harvard and the University of Michigan. He has served patients throughout ...
(Date:9/19/2017)... ... , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. To ... $835 million in resolved debt for its clients. , Credit card debt, unpaid hospital ... of debt settled by the company. With more than a decade of combined service ...
(Date:9/19/2017)... Dallas, TX (PRWEB) , ... September 19, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to Texas as a part of its national Swirl: ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology: